Lucid Diagnostics (LUCD) has recently closed a public offering of common stock, following an increase in position size by investors around the $1.2 area. Venus Concept (VERO) announced the closing of a $1.5 million registered direct offering of common stock, priced at-the-market under Nasdaq rules. Additionally, Verve Therapeutics (VERV) received U.S. FDA Fast Track designation for its in vivo base editing medicine, VERVE-102, which targets PCSK9. This designation aims to facilitate development and expedite review for drugs intended to treat serious conditions. The stock price of VERV increased by 9.8% in pre-market trading following the announcement. In contrast, Innovative Eyewear, Inc. (LUCY) experienced a decline of 32.3% in pre-market trading after receiving $1.8 million from warrant exercise, as part of definitive agreements for the immediate exercise of outstanding warrants.